Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Non-radiographic Axial Spondyloarthritis
NCT02757352Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of ixekizumab in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Eli Lilly and Company. Started Aug 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02757352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757352.